Newleos Therapeutics, Inc., a Boston, MA-based medical stage neuroscience firm co-founded by Longwood Fund and seasoned leaders in CNS drug improvement, closed $93.5m Collection A financing.
The spherical was led by Goldman Sachs Options with participation from Novo Holdings A/S, Longwood Fund, DCVC Bio, and Arkin Bio Capital.
Co-founded by Longwood Fund, Federico Bolognani, M.D., Ph.D., and William Martin, Ph.D., and led by David Donabedian, Ph.D., Founding CEO, Newleos has a clinical-stage pipeline that was in-licensed from Roche which incorporates a number of oral small molecules focusing on novel mechanisms throughout a broad vary of indications together with generalized nervousness, social nervousness, substance use issues and cognitive impairment.
Its lead medical program, NTX-1955 (RO7308480), is a first-in-class GABAA-γ1 selective constructive allosteric modulator (PAM) designed to deal with nervousness issues with a differentiated mechanism of motion with out the uncomfortable side effects of at present out there remedies. NTX-1955 was designed to particularly modulate GABAergic transmission within the nervousness mind circuit by focusing on the γ1 (gamma-1) subunit-containing GABAA receptor, which is extremely enriched within the amygdala. By specializing in GABAA regulation within the amygdala, NTX-1955 has the potential to scale back nervousness whereas sparing different mind networks related to security liabilities. NTX-1955 has accomplished a complete non-clinical package deal and has been in Part 1 trials, together with single and a number of ascending dose research, drug-drug interplay and receptor occupancy research, demonstrating that it’s protected, nicely tolerated, mind penetrant and selective to GABAA-γ1. Newleos plans to analyze NTX-1955 in proof-of-concept medical research for the remedy of generalized nervousness dysfunction.
Newleos’ further clinical-stage property embrace NTX-1472 (RO6953958), NTX-2001 (ralmitaront), and NTX-1511 (basmisanil), which goal V1a, TAAR1 and GABAA-α5 receptors, respectively. NTX-1472 is a selective, brain-penetrant V1a antagonist poised to enter proof-of-concept research focusing on social nervousness dysfunction. A well-understood pathway, the V1a receptor is activated by arginine vasopressin (AVP), a nanopeptide structurally associated to oxytocin. Preclinical research have proven that blocking V1a reduces anxiety-like habits in a number of animal fashions. NTX-2001 is a TAAR1 partial agonist, which Newleos intends to review in substance use issues. TAAR1 activation inhibits the rewarding and reinforcing results of medicine from totally different courses together with psychostimulants, opioids and alcohol. NTX-1511 is a extremely selective damaging allosteric modulator (NAM) of the α5 (alpha-5) subunit of the GABAA receptor with the potential to handle cognitive impairment in rare-neurodevelopmental indications.
The Newleos Board of Administrators consists of Christoph Westphal, M.D., Ph.D., Founding Govt Chairman, Newleos Therapeutics and Founding Accomplice, Longwood Fund; Ming Cheah, Ph.D. Vice President, inside Life Sciences Investing at Goldman Sachs Options; Ray Camahort, Ph.D., Accomplice within the Enterprise Investments group at Novo Holdings US; and David Donabedian, Ph.D., Govt Accomplice, Longwood Fund, and Founding CEO, Newleos. As a part of the licensing settlement, Roche obtained an upfront cost and is eligible to obtain success-based milestones and royalties in trade for granting Newleos worldwide rights to the medical stage property.
FinSMEs
13/02/2025
